336 related articles for article (PubMed ID: 26164752)
1. The influence of a rectal ultrasound probe on the separation between prostate and rectum in high-dose-rate brachytherapy.
Rylander S; Buus S; Bentzen L; Pedersen EM; Tanderup K
Brachytherapy; 2015; 14(5):711-7. PubMed ID: 26164752
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of rectum dose-volume metrics for prostate external beam radiotherapy combined with brachytherapy: Evaluating deformably registered dose distribution addition using parameter-based addition.
Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):534-542. PubMed ID: 28185419
[TBL] [Abstract][Full Text] [Related]
3. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
6. Re-distribution of brachytherapy dose using a differential dose prescription adapted to risk of local failure in low-risk prostate cancer patients.
Rylander S; Polders D; Steggerda MJ; Moonen LM; Tanderup K; Van der Heide UA
Radiother Oncol; 2015 Jun; 115(3):308-13. PubMed ID: 26091576
[TBL] [Abstract][Full Text] [Related]
7. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
[TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric impact of contouring and needle reconstruction uncertainties in US-, CT- and MRI-based high-dose-rate prostate brachytherapy treatment planning.
Rylander S; Buus S; Pedersen EM; Bentzen L; Tanderup K
Radiother Oncol; 2017 Apr; 123(1):125-132. PubMed ID: 28284493
[TBL] [Abstract][Full Text] [Related]
10. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
12. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
[TBL] [Abstract][Full Text] [Related]
13. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
15. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
16. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
19. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy.
Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Pow-Sang JM; Spiess PE; Sexton WJ; Poch MA; Biagioli MC
Radiother Oncol; 2014 Apr; 111(1):126-31. PubMed ID: 24746567
[TBL] [Abstract][Full Text] [Related]
20. A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT.
Pettersson N; Johansson KA; Alsadius D; Tucker SL; Steineck G; Olsson C
Acta Oncol; 2014 Jun; 53(6):815-21. PubMed ID: 24460070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
